Parties d'ouvrages collectifs (1)
  1. 1. Lehtonen, E., & Tenenbaum, L. (2003). Adeno-associated viral vectors. In D. Lachtman (Ed.), Viral vectors for treating diseases of the nervous system (pp. 65-98). London-San Diego: Academic Press.(International review of neurobiology, 55).
    2.   Articles dans des revues avec comité de lecture (12)
  2. 1. Yang, X., Mertens, B., Lehtonen, E., Vercammen, L., Bockstael, O., Chtarto, A., Levivier, M., Brotchi, J., Michotte, Y., Baekelandt, V., Sarre, S., & Tenenbaum, L. (2009). Reversible neurochemical changes mediated by delayed intrastriatal glial cell line-derived neurotrophic factor gene delivery in a partial Parkinson's disease rat model. The journal of gene medicine, 11(10), 899-912. doi:10.1002/jgm.1377
  3. 2. Lubansu, A., Abeloos, L., Bockstael, O., Lehtonen, E., Blum, D., Brotchi, J., Levivier, M., & Tenenbaum, L. (2008). Recombinant AAV viral vectors serotype 1, 2, and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. Cell transplantation, 16(10), 1013-1020.
  4. 3. Chtarto, A., Yang, X., Bockstael, O., Melas, C., Blum, D., Lehtonen, E., Abeloos, L., Jaspar, J.-M., Levivier, M., Brotchi, J., Velu, T., & Tenenbaum, L. (2007). Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Experimental neurology, 204(1), 387-399. doi:10.1016/j.expneurol.2006.11.014
  5. 4. Tenenbaum, L., Chtarto, A., Lehtonen, E., Velu, T., Brotchi, J., & Levivier, M. (2004). Recombinant AAV-mediated gene delivery to the central nervous system. The journal of gene medicine, 6 Suppl 1, S212-S222. doi:10.1002/jgm.506
  6. 5. Tenenbaum, L., Peschanski, M., Melas, C., Rodesh, F., Lehtonen, E., Stathopoulos, A., Velu, T., Brotchi, J., & Levivier, M. (2004). Efficient early and sustained transduction of human fetal mesencephalon using adeno-associated virus type 2 vectors. Cell transplantation, 13(5), 565-571.
  7. 6. Tenenbaum, L., & Lehtonen, E. (2003). Virus vectors for use in the central nervous system: adeno-associated viral vectors. International review of neurobiology, 55, 65-98. doi:10.1016/S0074-7742(03)01002-X
  8. 7. Tenenbaum, L., Lehtonen, E., & Monahan, P. E. (2003). Evaluation of risks related to the use of adeno-associated virus-based vectors. Current gene therapy, 3(6), 545-565.
  9. 8. Tenenbaum, L., Lehtonen, E., & Monahan, P. E. (2003). Evaluation of risks related to the use of adeno-associated virus-based vectors. Current gene therapy, 3(6), 545-565.
  10. 9. Lehtonen, E., Blum, D., Bockstael, O., Chtarto, A., Melas, C., Peschanski, M., Velu, T., Brotchi, J., Levivier, M., & Tenenbaum, L. (2003). Effects of the sustained expression of GDNF in fetal dopaminergic grafts. Molecular therapy, 7, 95.
  11. 10. Chtarto, A., Bender, H. U., Hanemann, C. O., Kemp, T., Lehtonen, E., Levivier, M., Brotchi, J., Velu, T., & Tenenbaum, L. (2003). Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene therapy, 10(1), 84-94. doi:10.1038/sj.gt.3301838
  12. 11. Tenenbaum, L., Chtarto, A., Lehtonen, E., Blum, D., Baekelandt, V., Velu, T., Brotchi, J., & Levivier, M. (2002). Neuroprotective gene therapy for Parkinson's disease. Current gene therapy, 2(4), 451-483.
    13. << Précédent 1 2 Suivant >>